Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis
MedicalXpress
|
juil. 09, 2026
For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗